专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022138923A1 セラミド合成促進剤审中-公开
公开(公告)号：WO2022138923A1
公开(公告)日：2022-06-30
申请号：PCT/JP2021/048218
申请日：2021-12-24
申请人：株式会社エー・アイ・システムプロダクト
发明人：岡島　眞裕 , 池田　満雄 , 山本　博之
IPC分类号： A61K35/02 , A23L2/00 , A23L2/52 , A23L33/10 , A61K8/24 , A61K8/25 , A61K33/12 , A61K33/42 , A61P17/00 , A61P43/00 , A61Q19/00
摘要：本発明は、新規なセラミド合成促進剤を提供することを目的とする。本発明は、ケイ素及びリンを含有するミネラル塩を含む水溶液を電気分解して得られたアルカリイオン水を含むセラミド合成促進剤に関する。

2. 发明申请

WO2008030947A2 USE OF UNACTIVATED CALCIUM EXCHANGED ZEOLITES IN HEMOSTATIC DEVICES AND PRODUCTS 审中-公开
标题翻译：激活的钙交换沸石在催化装置和产品中的应用
公开(公告)号：WO2008030947A2
公开(公告)日：2008-03-13
申请号：PCT/US2007/077742
申请日：2007-09-06
申请人： UOP LLC , BEDARD, Robert, L.
发明人： BEDARD, Robert, L.
IPC分类号： A61L15/00 , A61K33/12
CPC分类号： A61K33/06 , A61K45/06 , A61L26/0004 , A61L2400/04 , Y10T442/2525
摘要： It is known that activated and partially activated zeolites are effective in hemostasis. However, the use of fully hydrated, unactivated zeolites has been ignored up to this point based upon a belief that it was necessary for such zeolites to concentrate certain components in the blood by removal of water. It has now been found that fully hydrated zeolites clot blood almost as quickly as fully activated zeolites that have been dehydrated without the potentially injurious exothermic response which may cause burns in tha case of fully activated zeolites.
摘要翻译：已知活化和部分活化的沸石在止血中是有效的。然而，基于认为这样的沸石必须通过去除水将某些组分浓缩在血液中而被认为是完全水合的，未活化的沸石的使用已被忽视。现在已经发现，完全水合的沸石几乎与已经脱水的完全活化的沸石一样快地凝血，没有潜在的有害的放热反应，这可能在完全活化的沸石的情况下引起灼伤。

3. 发明申请

WO01014468A1 ALGINATE PREPARATION AND USE OF THE SAME 审中-公开
标题翻译： ALGINATAUFBEREITUNG及其用途
公开(公告)号：WO01014468A1
公开(公告)日：2001-03-01
申请号：PCT/EP2000/008136
申请日：2000-08-21
IPC分类号： A61K31/35 , A61K31/695 , A61K31/715 , A61K31/734 , A61K33/00 , A61K33/06 , A61K33/12 , A61K36/03 , A61P1/00 , C08B37/04 , C08L5/04
CPC分类号： C08L5/04 , A61K31/35 , A61K31/695 , A61K31/715 , A61K33/00 , A61K33/06 , A61K33/12 , A61K36/03 , A61K31/70 , A61K2300/00
摘要： The invention relates to a mixture containing an alginate preparation based on alginate acid and/or its derivatives, optionally in salt form, together with at least one radical interceptor and at least one absorption agent. The mixture is used for treating malabsorption and in particular, AIDS.
摘要翻译：本发明是一种含有与Alginataufbereitung藻酸和/或它们的衍生物，任选以盐的形式的混合物，以及至少一种自由基清除剂和至少一种吸收剂。该混合物用于吸收障碍的治疗，特别是疾病爱滋病。

4. 发明申请

WO00015195A1 QUICK RELEASE PHARMACEUTICAL COMPOSITIONS OF DRUG SUBSTANCES 审中-公开
标题翻译：快速释放药物药物组合物
公开(公告)号：WO00015195A1
公开(公告)日：2000-03-23
申请号：PCT/DK1999/000480
申请日：1999-09-10
IPC分类号： A61K9/14 , A61K9/16 , A61K9/20 , A61K9/28 , A61K9/48 , A61K31/542 , A61K33/10 , A61K33/12 , A61K45/00 , A61K47/02 , A61K47/04 , A61K47/26 , A61P1/04 , A61P5/46 , A61P25/04 , A61P25/24 , A61P29/00 , A61P43/00
CPC分类号： A61K9/2009 , A61K9/1611
摘要： The present invention relates to an oral modified release pharmaceutical composition for the administration of a therapeutically and/or prophylactically effective amount of an active substance (a drug substance) to obtain a relatively fast or quick onset of the therapeutic and/or prophylactic effect. The drug substances contained in a modified release pharmaceutical composition according to the invention are suitably a drug substance which has a very low solubitity under acidic conditions, i.e. under conditions similar to those present in the stomach and/or drug substances which have a pKa value below about 5.5 such as in a range of from about 4 to about 5. The composition is based on a powder comprising a therapeutically and/or prophylactically active substance and has such a particle size that: when the powder is subjected to a sieve analysis, then at least about 90 % w/w of the particles passes through sieves 180 mu m and the powder is contacted with an aqueous medium to form a particulate composition, which has such a particle size that when the particulate composition is subjected to a sieve analysis, then at least about 50 % w/w of the particles passes through sieve 180 mu m. Furthermore, the composition, when tested in accordance with the dissolution method (I) defined herein employing 0.07 N hydrochloric acid as dissolution medium, releases at least about 50 % w/w of the active substance within the first 20 min of the test.
摘要翻译：本发明涉及用于给予治疗和/或预防有效量的活性物质（药物物质）以获得治疗和/或预防效果相对快速或快速发作的口服释放药物组合物。包含在根据本发明的调释释放药物组合物中的药物物质合适地是在酸性条件下具有非常低的溶解度的药物物质，即在与pKa值低于pKa值的胃和/或药物物质中存在的条件相似的条件下约5.5，例如在约4至约5的范围内。该组合物基于包含治疗和/或预防活性物质的粉末，并且具有如下的粒径：当粉末进行筛分分析时，则至少约90％w / w的颗粒通过180μm的筛子，并且粉末与水性介质接触以形成颗粒组合物，其具有这样的颗粒尺寸，即当颗粒组合物进行筛分分析时，那么颗粒的至少约50％w / w通过筛子180μm。此外，当根据本文定义的溶解方法（I）使用0.07N盐酸作为溶解介质测试时，组合物在试验的最初20分钟内释放至少约50％w / w的活性物质。

5. 发明申请

WO1987005217A1 PROCESS FOR THE PREPARATION OF A VISCOSITY-STABLE ANTACID COMPOSITION 审中-公开
标题翻译：制备粘度稳定的抗氧化剂组合物的方法
公开(公告)号：WO1987005217A1
公开(公告)日：1987-09-11
申请号：PCT/US1987000482
申请日：1987-03-05
申请人： RORER INTERNATIONAL (OVERSEAS) INC.
发明人： RORER INTERNATIONAL (OVERSEAS) INC. , LUBER, Joseph, Raymond , FELD, Kenneth, Marshall , HARWOOD, Richard, James , GRIM, Wayne, Martin
IPC分类号： A61K33/12
CPC分类号： A61K47/36 , A61K33/08 , A61K33/10
摘要： A process for the preparation of a viscosity-stable antacid composition containing an alginic acid salt comprising reacting an antacid material with said salt at elevated temperatures to form a reaction product and recovering said reaction product in stabilized form.

6. 发明申请

WO2022104962A1 一种益生菌体系的制备方法及其应用审中-公开
公开(公告)号：WO2022104962A1
公开(公告)日：2022-05-27
申请号：PCT/CN2020/135870
申请日：2020-12-11
申请人：南京大学
发明人：董磊 , 韩丛薇
IPC分类号： C12N1/20 , A61K35/747 , A61K35/745 , A61K35/741 , A61P35/00 , A61K33/00 , A61K33/06 , A61K33/12
摘要：本发明提供了一种益生菌体系的制备方法，通过使用该方法能够获得一种稳定的外源性益生菌体系，该益生菌体系经服用后可在宿主内形成稳定的微环境，能够起到改变肠道微生物群组成的效果，最终在恶性肿瘤治疗过程中发挥积极作用。

7. 发明申请

WO2022104959A1 一种益生菌体系及其应用审中-公开
公开(公告)号：WO2022104959A1
公开(公告)日：2022-05-27
申请号：PCT/CN2020/135847
申请日：2020-12-11
申请人：南京大学
发明人：董磊 , 韩丛薇
IPC分类号： C12N1/20 , A61K35/747 , A61K35/745 , A61K35/741 , A61P35/00 , A61K33/00 , A61K33/06 , A61K33/12
摘要：本发明提供了一种体系，该体系能够使外源益生菌在宿主内形成稳定的微环境，能够通过类似口服这样的简单方式进行施用，能够起到改变肠道微生物群组成的效果，最终在恶性肿瘤治疗过程中发挥积极作用。

8. 发明申请

WO2014201083A3 PHENOXYBENZAMINE TRANSDERMAL COMPOSITION 审中-公开
标题翻译：苯氧苯胺复合物
公开(公告)号：WO2014201083A3
公开(公告)日：2015-05-14
申请号：PCT/US2014041846
申请日：2014-06-11
申请人： PROFESSIONAL COMPOUNDING CT S OF AMERICA
发明人： GLASNAPP ANDREW B
IPC分类号： A61K33/12
CPC分类号： A61K31/138
摘要： A phenoxybenzamine transdermal composition for treating neuropathic pain is disclosed. The phenoxybenzamine transdermal composition may include phenoxybenzamine in a concentration of about 5 mg/g to about 120 mg/g, with about 15 mg/g being preferred, in combination with a pharmaceutically suitable permeation enhancer that may be included in amounts of about 20% by weight to about 99.95% by weight, with about 50% by weight being preferred. Permeation enhancer composition within disclosed phenoxybenzamine transdermal composition may improve penetration of phenoxybenzamine in a patient's tissue or skin. The phenoxybenzamine transdermal composition may provide a long duration blockade of sensitized pain receptors of 24 hours or more, resulting in an effective treatment for neuropathic pain with lower concentrations of phenoxybenzamine and requiring fewer applications.
摘要翻译：公开了用于治疗神经性疼痛的苯氧基苯甲胺透皮组合物。苯氧基苯甲胺透皮组合物可以包括浓度为约5mg / g至约120mg / g的苯氧基苯甲胺，其中优选约15mg / g，与药学上合适的渗透增强剂组合，其可以以约20％至约99.95重量％，优选约50重量％。所公开的苯氧基苯甲胺透皮组合物中的渗透增强剂组合物可以改善苯氧基苯甲胺在患者组织或皮肤中的渗透。苯氧基苯甲胺透皮组合物可提供24小时或更长时间的致敏疼痛受体的长时间阻断，导致用较低浓度苯氧基苯甲胺的神经性疼痛的有效治疗，并且需要较少的应用。

9. 发明申请

WO2009110940A3 VIRUS-, BACTERIA-, AND FUNGI-INTERACTING LAYERED PHYLLOSILICATES AND METHODS OF USE 审中-公开
公开(公告)号：WO2009110940A3
公开(公告)日：2009-09-11
申请号：PCT/US2008/086330
申请日：2008-12-11
申请人： AMCOL INTERNATIONAL CORPORATION , DARLINGTON JR., Jerald, W. , HUGHES, John , CONSTANTINIDES, Panayiotis, P. , FANG, Mingming , ST. ONGE, Jason, Harold
发明人： DARLINGTON JR., Jerald, W. , HUGHES, John , CONSTANTINIDES, Panayiotis, P. , FANG, Mingming , ST. ONGE, Jason, Harold
IPC分类号： A61K33/06 , A61K33/12 , A61K35/02 , A01N59/00 , A61P31/04
摘要： Layered phyllosilicates are useful for adsorbing and/or binding to and, thereby, inactivating viruses, bacteria and fungi. Accordingly, provided herein are methods of inactivating a virus, bacteria or fungus and methods of treating a viral, bacterial or fungal infection. Methods of delivering a therapeutic agent to a mammalian subject and methods of inactivating a virus in the gastrointestinal tract of an animal are also provided.

10. 发明申请

WO2009110940A2 VIRUS-, BACTERIA-, AND FUNGI-INTERACTING LAYERED PHYLLOSILICATES AND METHODS OF USE 审中-公开
标题翻译：病毒，细菌和真菌相互作用的层状物质及其使用方法
公开(公告)号：WO2009110940A2
公开(公告)日：2009-09-11
申请号：PCT/US2008086330
申请日：2008-12-11
申请人： AMCOL INTERNATIONAL CORP , DARLINGTON JR JERALD W , HUGHES JOHN , CONSTANTINIDES PANAYIOTIS P , FANG MINGMING , ST ONGE JASON HAROLD
发明人： DARLINGTON JR JERALD W , HUGHES JOHN , CONSTANTINIDES PANAYIOTIS P , FANG MINGMING , ST ONGE JASON HAROLD
IPC分类号： A61K33/06 , A01N59/00 , A61K33/12 , A61K35/02 , A61P31/04
CPC分类号： A61K35/02 , A01N59/00 , A61K33/06 , A61K33/12
摘要： Layered phyllosilicates are useful for adsorbing and/or binding to and, thereby, inactivating viruses, bacteria and fungi. Accordingly, provided herein are methods of inactivating a virus, bacteria or fungus and methods of treating a viral, bacterial or fungal infection. Methods of delivering a therapeutic agent to a mammalian subject and methods of inactivating a virus in the gastrointestinal tract of an animal are also provided.
摘要翻译：层状页硅酸盐可用于吸附和/或结合病毒，细菌和真菌，从而灭活病毒，细菌和真菌。因此，本文提供了灭活病毒，细菌或真菌的方法以及治疗病毒，细菌或真菌感染的方法。还提供了向哺乳动物受试者递送治疗剂的方法和在动物的胃肠道中灭活病毒的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式